BEIJING, Aug. 2, 2017 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced on behalf of its predecessor China Biologic Products, Inc. the unaudited financial results of China Biologic Products, Inc. for the second quarter of 2017.
Second Quarter 2017 Financial Highlights
Total sales in the second quarter of 2017 increased by 2.5% in RMB terms, or decreased by 2.3% in USD terms, to $89.3 million from $91.4 million in the same quarter of 2016.
Second Quarter 2017 Financial Highlights
Total sales in the second quarter of 2017 increased by 2.5% in RMB terms, or decreased by 2.3% in USD terms, to $89.3 million from $91.4 million in the same quarter of 2016.
